Please use this identifier to cite or link to this item:
Title: Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition
Author: Cervenka, Iris
Al Rahmoun, Marie
Mahamat-Saleh, Yahya
Fournier, Agnès
Boutron-Ruault, Marie-Christine
Severi, Gianluca
Caini, Saverio
Palli, Domenico
Ghiasvand, Reza
Veierod, Marit B.
Botteri, Edoardo
Tjønneland, Anne
Olsen, Anja
Fortner, Renée T.
Kaaks, Rudolf
Schulze, Matthias B.
Panico, Salvatore
Trichopoulou, Antonia
Dessinioti, Clio
Niforou, Katerina
Sieri, Sabina
Tumino, Rosario
Sacerdote, Carlotta
Bueno de Mesquita, H. Bas
Sandanger, Torkjel M.
Colorado Yohar, Sandra
Sánchez, Maria J.
Gil Majuelo, Leire
Luján Barroso, Leila
Ardanaz, Eva
Merino, Susana
Isaksson, Karolin
Butt, Salma Tunå
Ljuslinder, Infrid
Jansson, Malin
Travis, Ruth C.
Khaw, Kay-Tee
Weiderpass, Elisabete
Dossus, Laure
Rinaldi, Sabina
Kvaskoff, Marina
Keywords: Càncer de pell
Skin cancer
Issue Date: 15-Jun-2020
Publisher: Wiley
Abstract: Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country‐specific self‐administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline‐significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00-1.26), with no detected heterogeneity across countries (phomogeneity = 0.42). This risk increased linearly with duration of use (ptrend = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97-1.43), which was heterogeneous across countries (phomogeneity = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations.
Note: Versió postprint del document publicat a:
It is part of: International Journal of Cancer, 2020, vol. 146, num. 12, p. 3267-3280
Related resource:
ISSN: 0020-7136
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)

Files in This Item:
File Description SizeFormat 
704714.pdf231.05 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.